Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of HSD-016
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer (Industry)
Overall Status
Completed
CT.gov ID
NCT00740649
Collaborator
(none)
74
1
2
5
14.9
Study Details
Study Description
Brief Summary
This is a single ascending dose study of HSD-016 to provide the initial assessment of the safety, tolerability, how the drug is absorbed and eliminated, and it's effect on the body in Japanese male subjects.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
74 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Single Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of HSD-016 Administered Orally To Healthy Japanese Male Subjects
Study Start Date
:
Oct 1, 2008
Actual Primary Completion Date
:
Mar 1, 2009
Actual Study Completion Date
:
Mar 1, 2009
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 1 HSD-016 |
Drug: HSD-016
|
Other: 2 placebo |
Drug: placebo
|
Outcome Measures
Primary Outcome Measures
- clinical labs, adverse events [6 months]
Eligibility Criteria
Criteria
Ages Eligible for Study:
20 Years
to 45 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion:
-
Men, aged 20 to 45 years inclusive at screening.
-
Body mass index (BMI) in the range of 17.6 to 26.4 kg/m2 and body weight ≥45 kg
-
Healthy as determined by the investigator on the basis of screening evaluations.
-
Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history.
Exclusion:
-
No presence or history of any disorder that may prevent the successful completion of the study.
-
No history of drug abuse within 1 year.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Toshima-ku | Tokyo | Japan | 171-0014 |
Sponsors and Collaborators
- Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
- Study Director: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00740649
Other Study ID Numbers:
- 3248A1-1001
First Posted:
Aug 25, 2008
Last Update Posted:
Mar 31, 2009
Last Verified:
Mar 1, 2009